Solifenacin succinate
Solifenacin succinate Information

About Solifenacin succinate

Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.

Indications

Solifenacin succinate is primarily indicated in conditions like Urinary frequency and incontinence.

Contraindication

Solifenacin succinate is contraindicated in conditions like Narrow-angle glaucoma,Urinary retention,Urinary retention,Gastric retention,Hypersensitivity to any component of product.

Side Effects

The severe or irreversible adverse effects of Solifenacin succinate, which give rise to further complications include Angioneurotic edema, Intestinal obstruction, Respiratory depression.The signs and symptoms that are produced after the acute overdosage of Solifenacin succinate include Disorientation, Vomiting, Tachycardia, Blurred vision, Dry mouth, Urinary retention, Confusion, Respiratory depression, Ataxia, Respiratory depression, Angioedema, Tremor, Mydriasis, Agitation, Photophobia, Memory disturbance, Euphoria, Peripheral edema, Dry skin.The symptomatic adverse reactions produced by Solifenacin succinate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Constipation, Abdominal pain, Dry mouth, Blurred vision, Peripheral edema, Dyspepsia, Urinary retention, Dry eye.

Warnings

Incase of angioedema, if involvement of the tongue, hypopharynx, or larynx occurs, solifenacin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided. Administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention. Use with caution in patients with decreased gastrointestinal motility, narrow-angle glaucoma, reduced renal function, reduced hepatic function. Its doses greater than 5 mg are not recommended in patients with severe renal impairment (CLcr

High Risk Groups

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.